Literature DB >> 9311900

Competitive binding of viral E2 protein and mammalian core-binding factor to transcriptional control sequences of human papillomavirus type 8 and bovine papillomavirus type 1.

H M Schmidt1, G Steger, H Pfister.   

Abstract

The promoter P7535 of human papillomavirus type 8 and the promoter P7185 of bovine papillomavirus type 1 are negatively regulated by viral E2 proteins via the promoter proximal binding sites P2 and BS1, respectively. Mutations of these E2 binding sites can reduce basal promoter activity. This suggests binding of a transcription-stimulating factor and may indicate that repression by E2 is due to competitive binding of viral and cellular proteins. A computer search revealed putative binding sites for core-binding factor (CBF; also referred to as PEA2, PEBP2, or AML), overlapping with P2 and BS1. Binding of recombinant CBF proteins to these sites was confirmed by band shift analysis. Competition of CBF and E2 protein for DNA binding was shown for both human papillomavirus type 8 and bovine papillomavirus type 1. The importance of CBF-E2 competition in E2-mediated repression could be demonstrated by comparing the E2 effect on P7185 activity in two cell lines containing different amounts of endogenous CBF. In cells with large amounts of CBF, E2 repressed P7185 wild-type constructs to the basal promoter activity of a mutant (50%) that could not bind this protein any more. In contrast, in a cell line containing small amounts of CBF, the promoter activities of constructs with wild-type and mutated CBF binding sites hardly differed and specific repression by E2 was not detectable.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9311900      PMCID: PMC192167          DOI: 10.1128/JVI.71.10.8029-8034.1997

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  36 in total

1.  A ubiquitous repressor interacting with an F9 cell-specific silencer and its functional suppression by differentiated cell-specific positive factors.

Authors:  K Furukawa; Y Yamaguchi; E Ogawa; K Shigesada; M Satake; Y Ito
Journal:  Cell Growth Differ       Date:  1990-03

2.  A bovine papillomavirus constitutive enhancer is negatively regulated by the E2 repressor through competitive binding for a cellular factor.

Authors:  S B Vande Pol; P M Howley
Journal:  J Virol       Date:  1990-11       Impact factor: 5.103

3.  Purification of a mouse nuclear factor that binds to both the A and B cores of the polyomavirus enhancer.

Authors:  Y Kamachi; E Ogawa; M Asano; S Ishida; Y Murakami; M Satake; Y Ito; K Shigesada
Journal:  J Virol       Date:  1990-10       Impact factor: 5.103

4.  The E2 trans-activator can act as a repressor by interfering with a cellular transcription factor.

Authors:  A Stenlund; M R Botchan
Journal:  Genes Dev       Date:  1990-01       Impact factor: 11.361

Review 5.  Transcriptional repression of eukaryotic promoters.

Authors:  M Levine; J L Manley
Journal:  Cell       Date:  1989-11-03       Impact factor: 41.582

6.  Negative and positive factors determine the activity of the polyoma virus enhancer alpha domain in undifferentiated and differentiated cell types.

Authors:  B Wasylyk; J L Imler; B Chatton; C Schatz; C Wasylyk
Journal:  Proc Natl Acad Sci U S A       Date:  1988-11       Impact factor: 11.205

7.  Rapid detection of octamer binding proteins with 'mini-extracts', prepared from a small number of cells.

Authors:  E Schreiber; P Matthias; M M Müller; W Schaffner
Journal:  Nucleic Acids Res       Date:  1989-08-11       Impact factor: 16.971

8.  Bovine papillomavirus contains multiple transforming genes.

Authors:  Y C Yang; H Okayama; P M Howley
Journal:  Proc Natl Acad Sci U S A       Date:  1985-02       Impact factor: 11.205

9.  Human papillomavirus type 8 contains cis-active positive and negative transcriptional control sequences.

Authors:  H Reh; H Pfister
Journal:  J Gen Virol       Date:  1990-10       Impact factor: 3.891

10.  Dose-dependent regulation of the early promoter of human papillomavirus type 18 by the viral E2 protein.

Authors:  G Steger; S Corbach
Journal:  J Virol       Date:  1997-01       Impact factor: 5.103

View more
  7 in total

1.  Cooperative activation of human papillomavirus type 8 gene expression by the E2 protein and the cellular coactivator p300.

Authors:  Andreas Müller; Andreas Ritzkowsky; Gertrud Steger
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

2.  The E6 protein of the cutaneous human papillomavirus type 8 can stimulate the viral early and late promoters by distinct mechanisms.

Authors:  Andreas Müller-Schiffmann; Julia Beckmann; Gertrud Steger
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

3.  RUNX1 permits E4orf6-directed nuclear localization of the adenovirus E1B-55K protein and associates with centers of viral DNA and RNA synthesis.

Authors:  Leslie J Marshall; Amy C Moore; Misao Ohki; Issay Kitabayashi; David Patterson; David A Ornelles
Journal:  J Virol       Date:  2008-04-16       Impact factor: 5.103

4.  Human papillomavirus type 8 E2 protein unravels JunB/Fra-1 as an activator of the beta4-integrin gene in human keratinocytes.

Authors:  Monika Oldak; Radoslaw B Maksym; Tanya Sperling; Moshe Yaniv; Hans Smola; Herbert J Pfister; Jacek Malejczyk; Sigrun Smola
Journal:  J Virol       Date:  2009-11-18       Impact factor: 5.103

5.  The human papillomavirus type 8 E2 protein suppresses beta4-integrin expression in primary human keratinocytes.

Authors:  Monika Oldak; Hans Smola; Monique Aumailley; Francisco Rivero; Herbert Pfister; Sigrun Smola-Hess
Journal:  J Virol       Date:  2004-10       Impact factor: 5.103

Review 6.  The papillomavirus E2 proteins.

Authors:  Alison A McBride
Journal:  Virology       Date:  2013-07-10       Impact factor: 3.616

7.  SARS coronavirus 3b accessory protein modulates transcriptional activity of RUNX1b.

Authors:  Bhavna Varshney; Sudhakar Agnihothram; Sudhakar Agnihotram; Yee-Joo Tan; Ralph Baric; Sunil K Lal
Journal:  PLoS One       Date:  2012-01-12       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.